Does zafirlukast reduce future risk of asthma exacerbations in adults? Systematic review and meta-analysis

[1]  P. Gibson,et al.  Asthma control: how it can be best assessed? , 2014, Current opinion in pulmonary medicine.

[2]  S. Salvi,et al.  Insights, attitudes and perceptions about asthma and its treatment: Findings from a multinational survey of patients from 8 Asia‐Pacific countries and Hong Kong , 2013, Respirology.

[3]  Gang Wang,et al.  New insight into genes in association with asthma: literature‐based mining and network centrality analysis , 2013, Chinese medical journal.

[4]  H. Hakonarson,et al.  Genetic polymorphisms and associated susceptibility to asthma , 2013, International journal of general medicine.

[5]  P. Gibson,et al.  The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis. , 2013, The Journal of allergy and clinical immunology.

[6]  J. Lang,et al.  Asthma Severity, Exacerbation Risk, and Controller Treatment Burden in Underweight and Obese Children , 2012, The Journal of asthma : official journal of the Association for the Care of Asthma.

[7]  D. Zmirou-Navier,et al.  Diet, occupational exposure and early asthma incidence among bakers, pastry makers and hairdressers , 2012, BMC Public Health.

[8]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[9]  I. Pavord,et al.  A new perspective on concepts of asthma severity and control , 2008, European Respiratory Journal.

[10]  D. Johns,et al.  Tolerance and rebound with zafirlukast in patients with persistent asthma , 2008, Journal of Negative Results in BioMedicine.

[11]  Sean D Sullivan,et al.  Daily versus as-needed corticosteroids for mild persistent asthma. , 2005, The New England journal of medicine.

[12]  W. Busse,et al.  Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. , 2005, Chest.

[13]  L. Boulet,et al.  Cigarette smoking and asthma: a dangerous mix. , 2005, Canadian respiratory journal.

[14]  D. Fabian,et al.  The global burden of asthma: executive summary of the GINA Dissemination Committee Report , 2004, Allergy.

[15]  K. Juel,et al.  Asthma mortality in the Danish child population: risk factors and causes of asthma death , 2003, Pediatric pulmonology.

[16]  Horng-Chyuan Lin,et al.  Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study. , 2003, Chang Gung medical journal.

[17]  F. Ducharme.  Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence , 2003, BMJ : British Medical Journal.

[18]  L. Edwards,et al.  Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. , 2002, The American journal of medicine.

[19]  K. J. Macleod,et al.  Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma , 2002, Thorax.

[20]  S. Spector,et al.  Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[21]  R. Nathan,et al.  A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. , 2001, The American journal of medicine.

[22]  L. Edwards,et al.  Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. , 2001, The Journal of family practice.

[23]  D. Jamieson.  Rizatriptan. Comparative trial results. , 2010, Postgraduate medicine.

[24]  L. Edwards,et al.  Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[25]  J. Virchow,et al.  Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. , 2000, American journal of respiratory and critical care medicine.

[26]  L. Edwards,et al.  Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. , 2000, The Journal of allergy and clinical immunology.

[27]  W. Phipatanakul,et al.  A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge. , 2000, The Journal of allergy and clinical immunology.

[28]  S. Stoloff.  The role of LTRAs in the management of persistent asthma. , 2000, Postgraduate medicine.

[29]  W. Busse,et al.  Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. , 1999, The Journal of allergy and clinical immunology.

[30]  S. Spector,et al.  Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. , 1998, The Journal of allergy and clinical immunology.

[31]  J. Kemp,et al.  Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. , 1997, Clinical therapeutics.

[32]  G. Redding,et al.  Passive smoke exposure impairs recovery after hospitalization for acute asthma. , 1997, Archives of pediatrics & adolescent medicine.

[33]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[34]  S. Spector,et al.  Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. , 1994, American journal of respiratory and critical care medicine.